Introduction {#s1}
============

Diabetes mellitus and its chronic complications, such as foot problems, are prevalent worldwide. In fact, diabetic foot ulcer is the leading cause of nontraumatic amputation ([@B1]). That angiogenesis is crucial for wound healing is well known ([@B2],[@B3]). Endothelial progenitor cells (EPCs) play an important role in angiogenesis and neovascularization ([@B4]). However, much evidence shows that some aspects of EPC angiogenic ability, as measured by tube formation, adhesion, and migration, decrease in diabetes ([@B5],[@B6]). EPC-related angiogenic deficiency induced by diabetes causes chronic vascular complications, refractory wounds, and foot ulcers ([@B3],[@B7],[@B8]). Therefore, amendment of EPC function is a critical way to improve wound healing.

Mammalian tissues synthesize hydrogen sulfide (H~2~S) by two pyridoxal-5′-phosphate--dependent enzymes catalyzing the metabolism of [l]{.smallcaps}-cysteine: cystathionine β-synthase (CBS) and cystathionine-γ-lyase (CSE), as well as by a recently identified third pathway by the combined action of 3-mercapto-pyruvate sulfurtransferase and cysteine aminotransferase ([@B9],[@B10]). H~2~S has been considered a poisonous gas for a long time. However, evidence accumulating over the last decade shows that H~2~S could act as a novel gasotransmitter and take part in many physiological and pathological processes such as angiogenesis ([@B11]), vasodilation ([@B12]--[@B14]), and inhibition of apoptosis in vascular endothelial cells ([@B15]) and cardiomyocytes ([@B16]). In the cardiovascular system, the principal enzyme involved in the formation of H~2~S is CSE, which converts cystathionine to [l]{.smallcaps}-cysteine, yielding pyruvate, ammonia, and H~2~S ([@B17]). CSE is expressed in vascular endothelial cells, smooth muscle cells, and myocardial cells ([@B18]), but to date, whether CSE is expressed in the EPCs is unclear.

Regarding the relationship between H~2~S and diabetes, current evidence shows that the synthesis and circulating level of H~2~S decreases in NOD mice ([@B19]), in streptozotocin-induced type 1 diabetic mice ([@B20]), and in type 2 diabetic patients ([@B20]). H~2~S has been reported to accelerate gastric ulcer healing ([@B21]) and healing of burn wounds in the skin ([@B22],[@B23]). Papapetropoulos et al. ([@B22]) found that topical administration of H~2~S improved the recovery from burn wounds in wild-type rats and that genetic ablation of CSE delayed healing in mice. However, little is known about the role of H~2~S in chronic skin wound healing in diabetes, especially in type 2 diabetes. Whether H~2~S stimulates angiogenesis by influencing the functions of EPCs has also not been elucidated.

Angiopoietin (Ang) plays a major role in endothelial survival and vascular maturation. As a paracrine agonist, Ang-1 can induce phosphorylation of its receptor Tie 2 and promote endothelial survival and vessel stabilization ([@B24]). The Ang-1/Tie 2 signal has been reported to contribute to diabetes-induced angiogenesis impairment ([@B25],[@B26]), and reduced Ang-1 expression in high-glucose concentration downregulated the phosphatidyl inositol 3-kinase/Akt signaling pathway and phosphorylated endothelial nitric oxide (NO) synthase, which results in the impairment of EPC vessel-forming capacity ([@B25],[@B27]). Vascular endothelial growth factor (VEGF) has been reported as a proverbial factor to stimulate angiogenesis and mediate the improving course of wound healing ([@B28],[@B29]).

The current study aimed to test our hypothesis that H~2~S might improve angiogenesis and restore EPC function in an in vivo wound-healing *db*/*db* diabetic mouse model. We also investigated the expression of Ang-1 in wound skin tissue and EPCs because it is a possible important factor that mediates the angiogenic effects of H~2~S donors. Showing that controlling H~2~S can improve wound healing effectively and become a potential strategy for chronic lower extremity ulcerations in diabetic populations would be of great clinical significance.

Research Design and Methods {#s2}
===========================

Experimental Animals and Drugs {#s3}
------------------------------

All animal procedures were approved by and conducted in accordance with the Central South University Institutional Animal Care and Use Committee established guidelines. The B6.Cg- *m^+/+^Lepr^db^/J* (leptin receptor-deficient diabetes, *db*/*db*, 8--12 weeks, purchased from The Jackson Laboratory) mouse is a well-established type 2 diabetic animal model with continuous hyperinsulinemia and high plasma glucose levels ([@B30]). Their matched nondiabetic littermates (*db*/+) were used as controls.

H~2~S was administered in the form of sodium hydrosulfide (NaHS; Sigma-Aldrich) and 4-hydroxylthio-benzamide (4-HTB; Alfa Aesar), which is well established as a reliable H~2~S donor ([@B22],[@B31]). NaHS is a rapid-releasing H~2~S donor widely used in recent in vivo and in vitro H~2~S studies ([@B22],[@B23],[@B32]), and 4-HTB is a slow-releasing H~2~S donor that is effective in improving gastric ulcer healing in rats ([@B21]). [dl]{.smallcaps}-propargyl-glycine (PAG; Sigma-Aldrich), an irreversible competitive CSE inhibitor, was used to confirm the role of H~2~S in *db*/+ mice subjected to skin wounding ([@B33],[@B34]). Blood glucose from tail veins was measured with a rapid glucose meter (LifeScan OneTouch Ultra 2), and results were expressed as milligrams per deciliter. Diabetes was diagnosed when blood glucose was higher than 300 mg/dL.

Full-Thickness Excisional Dorsal Skin Wounds {#s4}
--------------------------------------------

Full-thickness punch biopsy wounds were created on male *db*/*db* mice and their age- and sex-matched *db*/+ mice, as we previously described ([@B35],[@B36]). Briefly, 6-mm-diameter full-thickness skin wounds were made on the dorsal skin with a biopsy punch (Acuderm Inc., Fort Lauderdale, FL). Wounds were dressed with Tegaderm (Nexcare, 3M) and changed every other day, and wound-closure rates were measured by tracing the wound area every other day onto an acetate paper. Gross wound closure was quantified by Image-Pro Plus 5.1 software (Media Cybernetics), and wound healing was expressed as the percentage of the original wound area that had healed, calculated as \[1 − (wound area day *x*/wound area day 0)\] × 100.

Animal Groups and Treatment {#s5}
---------------------------

Mice were randomly assigned to five groups: *db*/*db* plus NaHS (50 μmol ⋅ kg^−1^ ⋅ day^−1^, *n* = 9), *db*/*db* plus HTB (30 μmol ⋅ kg^−1^ ⋅ day^−1^, *n* = 9), *db*/*db* control (saline, *n* = 9), *db*/+ control (saline, *n* = 10), and *db*/+ plus DL-PAG (50 mg ⋅ kg^−1^ ⋅ day^−1^, *n* = 5). These drugs were injected intraperitoneally once daily from the day of wounding until 16 days later ([@B22],[@B23],[@B32]). At the end of 16 days, or at day 8 after wound creation, mice were killed under isoflurane anesthesia after the blood draw. Blood samples were drawn from the right ventricles by using syringes containing EDTA and then were centrifuged (10,000*g* at 4°C) for 10 min. Thereafter, plasma was aspirated and stored at −80°C for H~2~S concentration measurement. The skin wound tissues were carefully dissected, and granulation tissues within the wound as well as a 10-mm margin of wound were collected.

EPC Therapy for Diabetic Wounds {#s6}
-------------------------------

To determine whether H~2~S improves EPC-mediated wound healing in diabetes, 1 × 10^6^ diabetic EPCs were transplanted on *db*/*db* mouse wounds immediately after the skin punch biopsies. Described briefly, one group of *db*/*db* mice (*n* = 8) received an intraperitoneal injection of NaHS (50 μmol ⋅ kg^−1^ ⋅ day^−1^) every other day until 16 days later, and one group of *db*/*db* mice (*n* = 8) mice received an intraperitoneal injection of 0.9% saline every other day until 16 days later. These two groups of mice received topical transplants of 1 ×10^6^ diabetic EPCs on wounds, as we described previously ([@B35]). Another group of *db*/*db* (*n* = 8) mice used as a control only underwent skin punch biopsies.

Measurement of H~2~S Concentration in Plasma and CSE Activity in Skin Tissue {#s7}
----------------------------------------------------------------------------

H~2~S in the plasma was determined using previously described methods ([@B37]--[@B39]). Plasma (120 μL) was mixed with 100 μL water and 120 μL trichloroacetic acid (10% volume for volume), reacted for 10 min at room temperature, and then centrifuged (14,000*g* at 4°C) for 10 min. The clear supernatant was transferred to an Eppendorf tube, then Zn acetate (1%) 60 μL, N,N-dimethyl-p-phenylenediamine sulfate, 40 μL (20 mmol/L in 7.2 mol/L HCl), and FeCl~3~, 40 μL (30 mmol/L in 1.2 mol/L HCl), were added in proper sequence and reacted for 20 min at room temperature.

For CSE activity assay, the skin tissue was homogenized in an ice-cold 100 mmol/L potassium phosphate buffer (pH 7.4) with an electric homogenizer (PowerGen 125, Fisher Scientific). The homogenate was centrifuged (10,000*g* at 4°C) for 10 min, and the supernatant (430 μL in PBS) was mixed with 20 μL [l]{.smallcaps}-cysteine (20 mmol/L), 20 μL pyridoxal-5′-phosphate (2 mmol/L), and 30 μL 0.9% sodium chloride, and reacted for 30 min in a 37°C water bath. Then, 250 μL Zn acetate (1%) and 250 μL trichloroacetic acid (10%) were added to terminate the reaction. After that, N,N-dimethyl-p-phenylenediamine sulfate, 133 μL (20 mmol/L in 7.2 mol/L HCl), and FeCl~3~, 133 μL (30 mmol/L in 1.2 mol/L HCl), were added. The absorbance of the standards and samples at 670 nm was measured on a spectrophotometer (SpectraMax 190, Molecular Devices) after 20 min. H~2~S concentration was calculated against a calibration curve of NaHS (3.125--200 μmol/L) ([@B39]). All samples were assayed in duplicate. Results were expressed as plasma H~2~S concentration in micromole per liter. The optimal density value of skin samples obtained at 670 nm was adjusted by protein concentration and extrapolated from the standard curve obtained from the same plate. Results of CSE activity were expressed as H~2~S concentration in micromoles per microgram of protein.

Isolation and Culture of Bone Marrow--Derived EPCs {#s8}
--------------------------------------------------

EPCs were isolated from the bone marrow of *db*/+ and *db*/*db* mice and cultured afterward according to our established methods with minor modifications ([@B35],[@B40]). Described briefly, bone marrow mononuclear cells were isolated from the femurs and tibias of mice by density gradient centrifugation. After two washing steps, mononuclear cells were plated onto vitronectin-coated (Sigma-Aldrich) six-well plates and maintained in endothelial basal medium-2 (Lonza) supplemented with endothelial growth medium 2 (EGM-2, Lonza) with 5% FBS. Cells were cultured at 37°C with 5% CO~2~ in a humidified atmosphere. EPCs after 7 days of culture were used for further analysis. To characterize EPCs isolated from bone marrow, stem cell markers (CD34, Sca-1), endothelial cell markers (Flk-1, CD144), and monocyte marker (CD11b) were examined on cultured EPCs by flow cytometry according to our established methods ([@B35],[@B41]).

Cytotoxicity Assay {#s9}
------------------

The CellTiter 96 AQ~ueous~ One Solution Cell Proliferation Assay kit (Promega) was used to determine the cytotoxicity of NaHS and PAG in the in vitro studies. Described briefly, 2 × 10^4^ EPCs in 100 μL media were dispensed into each well of 96-well culture plates and cultured overnight. Plates were incubated for 30 min with NaHS (100 μmol/L) or PAG (100 nmol/L). A total of 20 μL of the CellTiter 96 AQ~ueous~ One Solution Reagent containing tetrazolium compound (3-\[4,5-dimethylthiazol-2-yl\]-5-\[3-carboxymethoxyphenyl\]-2-\[4-sulfophenyl\]-2H-tetrazolium, MTS) and an electron coupling reagent (phenazine ethosulfate; PES) was added to each well. Two hours later, the absorbance was recorded at 490 nm using a 96-well plate reader (Molecular Devices, Sunnyvale, CA).

H~2~S Treatment by NaHS in Diabetic EPCs {#s10}
----------------------------------------

EPCs isolated from *db*/*db* mice were reseeded into six-well plates at 5 × 10^5^ cells/well, incubated at 37°C for 24 h, and serum starved for 8 h. Then they were treated with NaHS at concentrations of 10, 50, and 100 μmol/L in EGM-2 medium for 30 min in a 37°C incubator before function evaluation.

CSE Knockdown by Small Interfering RNA in Normal EPCs {#s11}
-----------------------------------------------------

After 7 days in culture, EPCs from *db*/+ mice were reseeded into six-well plates at 2 × 10^5^ cells/well and incubated at 37°C until the cells were 60%--80% confluent. After that, EPCs were serum starved for 6 h before small interfering (si)RNA transfection. The EPC-conditioned media on CSE-siRNA (sc-142618, Santa Cruz Biotechnology) was diluted to a 10 μmol/L working solution and delivered to cells at a 5 nmol/L final concentration through a siRNA transfection reagent (sc-29528, Santa Cruz Biotechnology). After 5--7 h of transfection, the transfection mixture was removed and replaced with fresh EGM-2 and incubated for an additional 48 h. A nonrelated scrambled sequence siRNA (Control siRNA-A, sc-37007; Santa Cruz Biotechnology) was used as a transfection control.

CSE Inhibition by DL-PAG in Normal EPCs {#s12}
---------------------------------------

EPCs isolated from *db*/+ mice and cultured for 7 days were reseeded into six-well plates at 5 × 10^5^ cells/well and incubated at 37°C for 24 h, then serum starved for 6 to 8 h and treated with DL-PAG at concentrations of 3, 10, and 30 mmol/L in medium for 30 min; the medium containing PAG was then removed and washed twice with PBS for function assay.

Ang-1 Knockdown by siRNA in H~2~S-Treated Diabetic EPCs {#s13}
-------------------------------------------------------

EPCs isolated from *db*/*db* mice were reseeded into six-well plates at 5 × 10^5^ cells/well, incubated at 37°C for 24 h, and serum starved for 8 h. Then, the EPC-conditioned media on Ang-1 siRNA (Dharmacon) was diluted and delivered to cells at a 5 nmol/L concentration through a siRNA transfection reagent (Dharmacon). After 6 to 7 h, the transfection mixture was removed and replaced with fresh EGM-2 and incubated for an additional 48 h before 30-min NaHS treatment at concentration of 50 μmol/L. Of the nonrelated scrambled sequence siRNA--treated *db*/*db* EPCs, only NaHS 50 μmol/L--treated *db*/*db* EPCs and the untreated *db*/+ EPCs were used as controls. EPC tube formation was assessed after this treatment.

EPC Tube Formation and Adhesion Assays {#s14}
--------------------------------------

For the tube formation assay, 48-well plates were coated with growth factor--reduced Matrigel (150 μL/well, Becton, Dickinson and Co.). EPCs (5 × 10^4^), prepared as described above, were plated in 200 μL EGM-2 medium and incubated at 37°C with 5% CO~2~ for 12 h overnight to form the tube. Images of tube morphology in a random five fields per well were taken by inverted microscope (Nikon Eclipse TE2000-U) at original magnification ×4 ([@B23]). Tube lengths were drawn with Adobe Photoshop CS4 software and analyzed with Image-Pro Plus 5.1 software. For adhesion assay, EPCs were plated at 2.5 × 10^4^/well in triplicate to a vitronectin precoated 96-well plate. After 2 h of incubation at 37°C with 5% CO~2~ in EGM-2, nonadherent cells were removed by washing twice with PBS. Cells were fixed with 2% paraformaldehyde (PFA) for 20 min, and the nuclei were stained with Hoechst (5 μg/mL, Sigma-Aldrich) for 20 min. The adherent cells were counted in five random fields in each well with an inverted fluorescence microscope (Nikon) at original magnification ×10, and the mean value of three wells was determined for each sample.

Immunohistochemistry {#s15}
--------------------

Capillary density was quantified by histological analysis as previously described ([@B35]). At day 8 after wounding, round-shaped 6-mm skin samples, including the healed or unhealed wound area, were fixed with 2% PFA (Sigma-Aldrich), embedded in a cross-section position in paraffin, and sectioned at 4-μm intervals. Slides were deparaffinized and hydrated, blocked with normal rabbit serum (Vector Laboratories) for 30 min, incubated for 60 min at room temperature with an anti-CD31 antibody (1:50; Santa Cruz Biotechnology), and further incubated with Vectastain Elite ABC Reagent (Vector Laboratories) for 30 min and Nova Red (Vector Laboratories) for 15 min. Slides were counterstained with Gill (Lerner) 2 Hematoxylin (VWR Scientific) for 10 s, differentiated in 1% glacial acetic acid, and rinsed in running tap water. Photographs were taken under a Nikon Eclipse TE2000-U microscope using Metamorph software. Five random microscopic fields (original magnification ×20) were counted to determine the number of capillaries per wound, which was expressed as capillaries per high-power field.

Immunofluorescence and Confocal Microscopy {#s16}
------------------------------------------

EPCs were isolated as described above and cultured in EGM-2. BrdU staining was performed on EPCs as we previously described ([@B35]). Cultured EPCs were labeled with BrdU and 5-fluro-2′-deoxyuridine (BrdU labeling reagent, Invitrogen). Then, 1 × 10^6^ EPCs were transplanted to 6-mm punch biopsy wounds in *db*/*db* mice, as described above. On day 8 of wound healing, the mouse was killed, and the wound and surrounding skin was recovered and fixed in 2% PFA for 18 h. Samples were then switched to 70% ethanol. The samples were embedded in paraffin, and 4-mm sections were used for analysis. For staining with rabbit CD31 (1:50; Santa Cruz Biotechnology) and chicken BrdU (1:500; Abcam), primary antibodies were incubated overnight at 4°C. Slides were incubated with Alexa-488 (1:500; Invitrogen Molecular Probes) and Cy3 (1:1,000; Jackson ImmunoResearch Laboratory), followed by 30 s of incubation with Hoechst nuclear stain. Positively stained cells in five random fields were imaged at original magnification ×10 on a Nikon fluorescence microscope (Olympus, Melville, NY). Imaging conditions were maintained at identical settings with original gating performed within each antibody-labeling experiment with the negative control (no primary antibody).

Studies on Type 2 Diabetic Patients {#s17}
-----------------------------------

Eight nondiabetic and seven diabetic subjects underwent a full-skin excisional biopsy in their lower extremities. The nondiabetic subjects were recruited from patients admitted to the Division of Vascular Surgery of Shanghai Clinical Center because of traumatic wounds and did not have cardiovascular, renal, or hepatic disease. The diabetic subjects were recruited from Shanghai Clinical Center of Diabetes, and those who had foot or leg ulceration and underwent the debridement operation in our Division of Vascular Surgery were included in the study. The clinical characteristics of participating subjects are outlined in [Table 1](#T1){ref-type="table"}. All lower limb skin biopsies were performed during the limb operation by surgeons, and the skin beside the wound (margin within 1 cm) was taken. Protocols were approved by the institutional review boards of Shanghai Jiao Tong University and the Shanghai Clinical Center of Diabetes. Written informed consent was obtained from every subject. The skin tissues were used to examine the expressions of Ang-1, CSE, and VEGF by Western blot.

###### 

Clinical characteristic of participating subjects

![](1763tbl1)

Western Blot Analysis {#s18}
---------------------

Total protein was extracted from cultured EPCs after in vitro culture and treatment, as described above, or from harvested wound skin tissue, including a 6-mm region of skin located in the wound and 10 mm of skin tissue around the wound bed, by homogenization of skin wounds in tissue lysis buffer (Sigma-Aldrich). Protein concentration was determined by a bicinchoninic acid protein assay kit (Pierce). Equal amounts of proteins (30--50 μg) were boiled and separated by 6--12% SDS-PAGE and transferred onto nitrocellulose membrane (Amersham Hybond-ECL, GE Healthcare). CSE (mouse monoclonal anti-CSE, Santa Cruz Biotechnology), CBS (mouse monoclonal anti-CBS, Santa Cruz Biotechnology), and Ang-1 (rabbit polyclonal anti--Ang-1, Abcam) were determined with its specific first antibodies. The dilutions of primary antibody were 1:500 for Ang-1, 1:10000 for β-actin (Santa Cruz Biotechnology), and 1:250 for all other antibodies. Luciferin-conjugated secondary antibody was used at 1:5000. The bands were scanned and analyzed by the Odyssey system.

Statistical Analysis {#s19}
--------------------

Results are expressed as mean ± SEM. Differences between the two groups were compared with paired or unpaired Student *t* tests. One-way ANOVA with Tukey multiple comparison tests were used to compare each parameter when there were two or more independent groups. Two-way ANOVA of grouped analyses was used to compare the wound recovery rate at different time points, and then Bonferroni post hoc *t* tests were performed to compare replicate means by row when ANOVA was statistically significant. Values of *P* \< 0.05 were considered statistically significant.

Results {#s20}
=======

H~2~S Donor Therapy Corrected Decreased Plasma Concentration of H~2~S and CSE Activity in Diabetic Mice Skin Tissue {#s21}
-------------------------------------------------------------------------------------------------------------------

At 8--10 weeks of age, the body weights of the *db*/*db* mice were significantly greater than those of the *db*/+ mice (40.06 ± 3.37 g vs. 25.99 ± 1.22 g; *P* \< 0.01), and the blood glucose levels of the *db*/*db* mice were significantly higher than those of the *db*/+ mice (475.89 ± 42.27 mg/dL vs. 139.9 ± 33.49 mg/dL; *P* \< 0.01). The baseline plasma H~2~S concentration of the *db*/+ mice was significantly higher than that of the *db*/*db* mice ([Fig. 1*A*](#F1){ref-type="fig"}). The plasma H~2~S concentrations of the *db*/*db* mice were further decreased than those of *db*/+ mice after wound creation and were reversed by NaHS and HTB at day 8 ([Fig. 1*B*](#F1){ref-type="fig"}) and day 18 ([Fig. 1*C*](#F1){ref-type="fig"}). In contrast, PAG downregulated the H~2~S plasma concentrations in the *db*/+ mice ([Fig. 1*B* and *C*](#F1){ref-type="fig"}). Although the baseline level of H~2~S synthase CSE activity in the skin tissue of *db*/*db* mice was higher than in that of the *db*/+ mice ([Fig. 1*D*](#F1){ref-type="fig"}), the CSE activity of the *db*/*db* mice was significantly lower compared with that of the *db*/+ mice after wound creation at day 8 ([Fig. 1*E*](#F1){ref-type="fig"}).

![The plasma level of H~2~S and CSE activity in wound skin tissue was decreased in diabetic mice, which was reversed by it donors. *A*: Baseline of plasma H~2~S level in *db*/+ and *db*/*db* mice (*n* = 5 each group). \**P* \< 0.05 vs. *db*/+. *B*: Plasma H~2~S level at day 8 after wound establishment and H~2~S donor or PAG treatment (*n* = 5 in each group). \**P* \< 0.01 vs. *db*/+ control; \#*P* \< 0.01 vs. *db*/*db* control. *C*: Plasma H~2~S concentrations at day 16 after wound creation and H~2~S donor or PAG treatment (*n* = 5 each group). \**P* \< 0.05 vs. *db*/+ control; \#*P* \< 0.05 vs. *db*/*db* control. *D*: Baseline of the activity of H~2~S synthase CSE in the skin tissue of *db*/+ and *db*/*db* mice (*n* = 5 in each group). \**P* \< 0.05 vs. *db*/+. *E*: There was less CSE activity in the skin tissue of *db*/*db* mice than in *db*/+ mice (*n* = 5 in each group). \**P* \< 0.01 vs. *db*/+ control.](1763fig1){#F1}

H~2~S Therapy Accelerated Wound Healing in Diabetic Mice {#s22}
--------------------------------------------------------

The baselines of wound healing in *db*/*db* and *db*/+ mice were determined. The data demonstrated that the wound areas of the *db*/*db* mice closed significantly slower than those of the *db*/+ mice from day 2 to day 16 ([Fig. 2*A* and *B*](#F2){ref-type="fig"}). The administration of the rapid-releasing NaHS or slow-releasing HTB H~2~S donor improved wound recovery rates compared with saline-treated *db*/*db* controls ([Fig. 2*B* and *C*](#F2){ref-type="fig"}) starting from day 2 to day 16. The overall wound-healing rate in the two H~2~S donor groups was still slower than that of the *db*/+ group ([Fig. 2*B* and *C*](#F2){ref-type="fig"}). In contrast, the administration of H~2~S synthase CSE inhibitor, DL-PAG, significantly delayed the wound closure rate compared with the *db*/+ group ([Fig. 2*B* and *C*](#F2){ref-type="fig"}). These data suggest that H~2~S treatment improved wound healing in type 2 diabetic mice, whereas the inhibition of H~2~S synthesis in vivo delayed the wound-healing course.

![H~2~S rapid-releasing (NaHS) and slow-releasing donor (HTB) both accelerated wound healing in diabetic mice, but the CSE inhibitor PAG delayed the wound-closure rate in matched *db*/+ controls. Mice were randomly assigned to five groups: *db*/*db* plus NaHS (50 μmol ⋅ kg^−1^ ⋅ day^−1^, *n* = 9), *db*/*db* plus HTB (30 μmol ⋅ kg^−1^ ⋅ day^−1^, *n* = 9), *db*/*db* control (saline, *n* = 9), *db*/+ control (saline, *n* = 10), and *db*/+ plus DL-PAG (50 mg ⋅ kg^−1^ ⋅ day^−1^, *n* = 5). Full-thickness punch biopsy wounds (6-mm diameter) were created on these five groups of mice. Wound-closure rates were measured by tracing the wound area every other day, and gross wound closure was quantified by Image-Pro Plus 5.1. *A*: Photographs show representative wounds with time after wound performance in five groups. *B* and *C*: Comparisons of wound-closure rates in the five groups were expressed by the percentage of closed wound area. \**P* \< 0.05 *db*/*db* vs. *db*/+ or PAG group; \#*P* \< 0.05 *db*/+ vs. PAG group; &*P* \< 0.05 *db*/*db* vs. HTB or NaHS group.](1763fig2){#F2}

Slow-Releasing H~2~S Donor Stimulates Angiogenesis of Wound Skin Tissue {#s23}
-----------------------------------------------------------------------

At day 8 after treatments, capillary numbers in the diabetic group were significantly lower than those in the normal control group ([Fig. 3*A* and *B*](#F3){ref-type="fig"}). The slow-releasing H~2~S donor HTB significantly increased the newly formed capillary densities compared with that of diabetic controls ([Fig. 3*A* and *B*](#F3){ref-type="fig"}), whereas the vessel densities in skin tissue treated by NaHS augmented the newly formed capillary densities to some extent but without reaching statistical significance. On the contrary, new vessel densities were lower in wound skin taken from mice treated with PAG than from wound skin taken from normal *db*/+ controls ([Fig. 3*A* and *B*](#F3){ref-type="fig"}). The difference in the baselines of capillary numbers of unwounded skin between *db*/+ mice and *db*/*db* mice was not significant ([Fig. 3*C*](#F3){ref-type="fig"}).

![H~2~S donor stimulated angiogenesis in wound skin from *db*/*db* mice. The granule skin tissue within the wound area was collected at day 8 after NaHS, HTB, or PAG treatment and stained with CD31. *A*: Representative photomicrographs of new capillaries in five groups at original magnifications ×4 (*left*) and ×20 (*right*). The black dashed lines indicate the original wound edges, the black boxes indicate the areas enlarged correspondingly in the ×20 magnification panels, and the black arrows point to CD31-positive capillaries. *B*: Comparison of capillary numbers per high-power field (hpf) in five groups (*n* = 5 in each group). \**P* \< 0.05 vs. *db*/+ control, \#*P* \< 0.05 vs. *db*/*db* control. *C*: Comparison of capillary number in unwounded skin in *db*/+ mice and *db*/*db* mice (*n* = 5 each group).](1763fig3){#F3}

H~2~S Donor Accelerated the Rate of EPC-Mediated Wound Healing in Diabetic Mice {#s24}
-------------------------------------------------------------------------------

Wound healing improved significantly in the diabetic mice that received EPC transplantation. Furthermore, NaHS significantly augmented the efficiency of EPC cell therapy in diabetic mice (*P* \< 0.05 vs. *db*/*db* mice; [Fig. 4*A* and *B*](#F4){ref-type="fig"}). These data suggest that H~2~S significantly accelerated EPC-mediated wound healing in diabetic mice. On day 8 of wound beds, some BrdU-labeled EPCs integrated into vascular-like structures (CD31-positive) and the other BrdU-labeled EPCs integrated in the dermis. On day 16 of wound beds, more BrdU-labeled cells integrated into the epithelial layers ([Fig. 4*C*](#F4){ref-type="fig"}).

![H~2~S donor accelerated the rate of EPC-mediated wound healing in diabetic mice. One group of *db*/*db* mice (*n* = 8) received an intraperitoneal injection of NaHS (50 μmol ⋅ kg^−1^ ⋅ day^−1^) every other day for 16 days (*db*/*db* + NaHS Tx EPCs), and one group of *db*/*db* mice (*n* = 8) mice received an intraperitoneal injection of 0.9% saline every other day for 16 days (*db*/*db* + saline Tx EPCs). These two groups of mice received topically transplanted (Tx) 1 ×10^6^ diabetic EPCs on wounds immediately after skin punch biopsies. Another group of *db*/*db* mice (*n* = 8) used as control only underwent skin punch biopsies (*db*/*db* only). *A*: Photographs of representative wounds, with time after wound performance, in the three groups. *B*: Comparisons of the wound-closure rates in the three groups were expressed by the percentage of closed wound area. \**P* \< 0.05 *db*/*db* vs.*db/db +* NaHS Tx EPCs or *db*/*db* + saline Tx EPCs; \#*P* \< 0.05 *db/db +*NaHS Tx EPCs vs. *db*/*db* + saline Tx EPCs. *C*: Representative photographs demonstrated EPC integration into the dermis and vascular structure. On day 8 of wound beds, some BrdU-labeled EPCs (green fluorescence) integrated into vascular-like structures (CD31-positive, red fluorescence), and the other BrdU-labeled EPCs integrated in the dermis. On day 16 of wound beds, more BrdU-labeled EPCs integrated into the epithelial layers. The nuclei were counterstained with DAPI (blue fluorescence). The merged image is shown in *C*. The skin sample was imaged at original magnification ×10 using a Nikon 90i upright microscope. Scale for ×10 = 200 μm.](1763fig4){#F4}

H~2~S Donor Improved Tube Formation and Adhesive Function of Diabetic EPCs {#s25}
--------------------------------------------------------------------------

To investigate the functions of EPCs, EPC tube formation on Matrigel and EPC adhesion in vitronectin precoated plates were observed in EPCs isolated from mice after 16 days of treatment with H~2~S or PAG. The cell population profiles of cultured EPCs (day 7) were as follows: Sca-1 (60.8 ± 7.52%), CD34 (47.6 ± 4.37%), Flk-1 (22.6 ± 3.17%), CD144 (8.7 ± 1.19%), and CD11b (37.5 ± 2.54%), indicating that 7-day cultured EPCs are heterogeneous populations containing both higher percentages of stem cells and endothelial cells. The *db*/*db* EPCs formed significantly fewer tube networks than the *db*/+ EPCs ([Fig. 5*A*](#F5){ref-type="fig"}). In vivo H~2~S therapy with NaHS and HTB significantly improved the ability of diabetic EPCs to form tube networks compared with *db*/*db* control EPCs ([Fig. 5*A*](#F5){ref-type="fig"}). On the contrary, PAG treatment significantly reduced the tube length compared with normal controls ([Fig. 5*A*](#F5){ref-type="fig"}). Similar to tube formation, the adhesive numbers of EPCs in the *db*/*db* group was markedly less than that in the normal group ([Fig. 4*B*](#F4){ref-type="fig"}), and administration of NaHS and HTB significantly increased the adhesion function of EPCs compared with untreated *db*/*db* EPCs ([Fig. 5*B*](#F5){ref-type="fig"}). Contrarily, EPC adhesion in the PAG group was significantly attenuated compared with that of the *db*/+ control group ([Fig. 4*B*](#F4){ref-type="fig"}).

###### 

H~2~S donor restored the EPC functions of diabetic mice in vivo and in vitro*,* whereas H~2~S inhibition suppressed the angiogenic functions of normal EPCs. EPCs were isolated from the bone marrow of five groups after 16 days of in vivo treatment and cultured in EGM-2 for 7 days before assay or collected directly from *db*/*db* or *db*/+ mice. The reseeded EPCs (5 × 10^5^) were treated in vitro with NaHS 10, 50, or 100 μmol/L in EGM-2 for 30 min; PAG 3, 10, or 30 mmol/L in EGM-2 for 30 min; or CSE-siRNA at 50 nmol/L in medium for 6--7 h after 6--8 h of serum starvation before tube formation on Matrigel and adhesion assay. *A*: Representative tube network photographs under a microscope (original magnification ×4) and comparison of tube length among five groups after 16 days of in vivo treatment of H~2~S donor (*n* = 4--5). \**P* \< 0.01 PAG vs. *db*/+ control, *db*/*db* vs. *db*/+; \#*P* \< 0. 01 NaHS vs. *db*/*db*, HTB vs. *db*/*db* control. *B*: Comparison of adhesive cell numbers of five groups (*n* = 3--5). \**P* \< 0.01 *db*/*db* vs. *db*/+, PAG vs. *db*/+ control; \#*P* \< 0.01 NaHS vs. *db*/*db* and HTB vs. *db*/*db* control. *C*: Photographs of representative tube networks under microscope (original magnification ×4) and comparison of tube length in four groups treated with different NaHS concentrations and controls (*n* = 3--4). \**P* \< 0.01 vs. *db*/*db* control. *D*: Comparison of the adhesive EPC numbers of four groups treated with different NaHS concentrations and controls (*n* = 5). \**P* \< 0.01 vs. *db*/*db* control. *E*: Representative photographs of tube networks under microscope (original magnification ×4) and comparison of mean tube length in four groups with in vitro PAG at 3, 10, or 30 mmol/L treatment (*n* = 5 each group). \**P* \< 0.01 vs. control. *F*: Comparison of adhesive cells numbers in four groups with different concentrations of PAG treatment (*n* = 4). \**P* \< 0.01 vs. *db*/+ control. *G*: CSE silencing with CSE-siRNA in normal EPCs inhibited the CSE expression by 70% in siCSE transfected EPCs (*n* = 4--5). \**P* \< 0.01 vs. control. *H*: CSE silencing did not alter the CBS expression of normal EPCs. *P* \> 0.05 vs. control. *I*: The tube length of EPCs after CSE silencing decreased by nearly 40% (*n* = 7 in each group). \**P* \< 0.01 vs. control. *J*: The adhesive EPC numbers decreased by 55% in CSE-silenced EPCs (*n* = 4 in each group). \**P* \< 0.01 vs. control. *K*: Cell viability was not affected by 100 μmol/L NaHS or 30 mmol/L PAG (*n* = 4--5). *P* \> 0.05.
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To observe the influence of H~2~S on the functions of diabetic EPCs in vitro, EPCs isolated from the bone marrow of *db*/*db* mice were treated with NaHS at concentrations of 10, 50, and 100 μmol/L in EMG-2 for 30 min before tube formation and adhesion determination. NaHS significantly augmented the tube networks of diabetic EPCs at all three concentrations compared with nonmodified *db*/*db* EPCs ([Fig. 5*C*](#F5){ref-type="fig"}). The deficient adhesion of diabetic EPCs was also reversed by NaHS with concentrations of above 10 μmol/L in vitro ([Fig. 5*D*](#F5){ref-type="fig"}). These aforementioned data suggest that in vivo and in vitro H~2~S donor treatment both restore deficient EPC tube formation and adhesive functions in *db*/*db* mice.

H~2~S Inhibition With DL-PAG and CSE siRNA Reduced the Function of Normal EPCs In Vitro {#s26}
---------------------------------------------------------------------------------------

To verify whether H~2~S inhibition could impair EPC function, H~2~S synthesis of EPCs was inhibited with different concentrations of DL-PAG (3, 10, and 30 mmol/L), which was added to EGM-2 medium for 30 min. The results indicated that the tube length of EPCs treated with PAG 10 mmol/L and 30 mmol/L decreased significantly compared with that of normal controls ([Fig. 5*E*](#F5){ref-type="fig"}). Similarly, the adhesive EPC numbers were reduced markedly in the PAG 10 mmol/L and 30 mmol/L intervention groups compared with control EPCs ([Fig. 5*F*](#F5){ref-type="fig"}). These results suggest that the inhibition of H~2~S synthesis in EPCs reduces their functions.

The tube formation results from the CSE silencing experiment in EPCs further demonstrated the critical effect of H~2~S on EPC angiogenesis. The CSE expression of EPCs after siCSE treatment was reduced by nearly 70%, as shown by Western blotting ([Fig. 5*G*](#F5){ref-type="fig"}), whereas the expression of CBS was not influenced by the silencing of CSE in EPCs ([Fig. 5*H*](#F5){ref-type="fig"}). The average tube length of EPCs after CSE knockdown decreased to ∼40% compared with controls ([Fig. 5*I*](#F5){ref-type="fig"}), and EPC adhesion also was markedly attenuated compared with controls ([Fig. 5*J*](#F5){ref-type="fig"}). These data identified that H~2~S is critical for EPC functions, including tube formation and adhesion abilities. In addition, the cytotoxicity assay showed that treatment with NaHS or PAG did not affect the viability of EPCs ([Fig. 5*K*](#F5){ref-type="fig"}).

H~2~S Donor Upregulated Expressions of Ang-1 in Wound Skin Tissues and EPCs of Diabetic Mice, Whereas CSE Suppression Downregulated Ang-1 Expression in Normal EPCs {#s27}
-------------------------------------------------------------------------------------------------------------------------------------------------------------------

To understand the possible mechanism through which H~2~S improves EPC function, the expressions of Ang-1 and VEGF in wound skin tissue and EPCs were measured by Western blotting. The results indicated that the in vivo H~2~S donor treatment significantly increased the expressions of Ang-1 and VEGF not only in EPCs from these mice but also in wound skin tissues ([Fig. 6*A*--*C*](#F6){ref-type="fig"}). On the contrary, the CSE inhibitor PAG inhibited the expression of Ang-1 in the wound skin tissue ([Fig. 6*A*](#F6){ref-type="fig"}) and in EPCs ([Fig. 6*B*](#F6){ref-type="fig"}). Similarly, the silencing of CSE in cultured normal EPCs with CSE siRNA in vitro treatment significantly decreased their Ang-1 expression ([Fig. 6*D*](#F6){ref-type="fig"}).

![H~2~S donor upregulated the expressions of Ang-1 in wound skin tissues and in EPCs in type 2 diabetes, whereas CSE suppression downregulated Ang-1 expression in normal EPCs. Protein was extracted from 6 mm of wound skin and 0.5 cm of skin outside of the wound, and 7-day cultured EPCs after 16 days of in vivo treatment by two H~2~S donors and PAG, or normal EPCs with in vitro CSE siRNA 50 nmol/L treatment and its controls. *A* and *B*: Protein bands and comparison of EPCs and skin tissue Ang-1 expression in five groups (*n* = 4--5). \**P* \< 0.01 PAG vs. *db*/+ control, *db*/*db* vs. *db*/+ control; \#*P* \< 0.01 NaHS vs. *db*/*db* control and HTB vs. *db*/*db* control. *C*: Protein bands and comparison of VEGF expression of EPCs in five groups (*n* = 4--5). \**P* \< 0.01 *db*/*db* vs. *db*/+. *D*: Protein bands and comparison of Ang-1 expression in EPCs with and without CSE siRNA treatment (*n* = 4--5). \**P* \< 0.01 vs. control.](1763fig6){#F6}

H~2~S Promoted Angiogenesis of EPCs by Restoration of Ang-1 Expression {#s28}
----------------------------------------------------------------------

To identify whether H~2~S stimulates the angiogenic function of EPCs through Ang-1 signaling, EPCs were pretreated with Ang-1 siRNA before in vitro NaHS treatment. EPCs were isolated from the bone marrow of *db*/*db* and normal mice and cultured in EGM-2 for 7 days. Diabetic EPCs (5 × 10^5^) were then reseeded and treated in vitro with NaHS at 50 μmol/L only in EGM-2 for 30 min or with Ang-1 siRNA at 5 nmol/L in medium for 6--7 h before NaHS treatment. The results revealed that the improved tube length with NaHS was significantly inhibited by prior Ang-1 siRNA treatment and was significantly lower than that of normal EPCs (all *P* \< 0.05; [Fig. 7*A* and *B*](#F7){ref-type="fig"}). These results suggest that H~2~S exerts its role of promoting EPC angiogenesis, at least partially, by restoration of Ang-1.

![H~2~S promoted EPC angiogenesis by restoration of Ang-1 expression. EPCs were isolated from bone marrow of *db*/*db* and normal mice and cultured in EGM-2 for 7 days, then *db*/*db* EPCs (5 × 10^5^) were reseeded and treated in vitro with NaHS 50 nmol/L only in EGM-2 for 30 min, or Ang-1 siRNA at 5 nmol/L in medium for 6--7 h before NaHS 50 nmol/L treatment. Then, tube formation on Matrigel and adhesion on vitronectin assay were performed in all EPCs. *A*: Representative photographs of tube networks under microscope (original magnification ×4). *B*: Comparison of tube length in four groups of *db*/+ EPCs and *db*/*db* EPCs treated with and without NaHS, NaHS and Ang-1 siRNA (*n* = 4 in each group). \**P* \< 0.05 vs. *db*/+, \#*P* \< 0.05 vs. *db*/*db* only.](1763fig7){#F7}

Expressions of Ang-1, CSE, and VEGF Were Decreased in the Human Skin Tissue of Diabetic Foot Ulcers {#s29}
---------------------------------------------------------------------------------------------------

To investigate whether the dysregulations of Ang-1, CSE, and VEGF also applied to the skin tissue from foot ulcers of diabetic subjects, we compared their expression between nondiabetic and type 2 diabetic subjects. The data showed that the expressions levels of Ang-1, CSE, and VEGF were 36%, 41%, and 46% lower, respectively, in the diabetic subjects compared with the nondiabetic subjects ([Fig. 8](#F8){ref-type="fig"}).

![The expressions of Ang-1, CSE, and VEGF were decreased in human skin tissue of diabetic foot ulcers. *A*: Representative protein bands of Ang-1, CSE, and VEGF of skin tissue. *B*: The expression of Ang-1, CSE, and VEGF were lower in the foot ulcer skin tissue of diabetic patients than in nondiabetic controls (*n* = 7--8 in each group). \*\**P* \< 0.05 vs. control. GAPDH, glyceraldehyde-3-phosphate dehydrogenase.](1763fig8){#F8}

Discussion {#s30}
==========

H~2~S is the "third" gasotransmitter next to NO and carbon monoxide (CO). Its biological effects have not yet been completely understood. The current study demonstrates that *1*) plasma H~2~S levels and CSE activities in skin wounds decreased in type 2 diabetic mice; *2*) in vivo and in vitro H~2~S treatment both amended the tube formation and adhesive functions of diabetic EPCs; *3*) H~2~S donor therapy improved EPC-mediated wound healing in diabetic mice via elevating angiogenesis; *4*) H~2~S treatment increased the expression of Ang-1 and VEGF in EPCs from diabetic mice and Ang-1 siRNA inhibited the ameliorative effect of NaHS on EPC angiogenic functions; and *5*) the expressions of Ang-1, CSE, and VEGF were decreased in diabetic ulcers in diabetic patients.

The baselines of plasma H~2~S in diabetic mice were significantly lower than those of the nondiabetic mice, which is consistent with the plasma H~2~S measurements in NOD mice ([@B19]) and streptozotocin-induced type 1 diabetic mice ([@B20]). On day 8 or day 16 after skin wounds, the plasma H~2~S levels were further decreased in the diabetic mice, whereas the plasma H~2~S levels in the nondiabetic mice were maintained at baseline level. Interestingly, the baseline activity of CSE in skin tissues was ∼1.3-fold higher in the diabetic mice than in the nondiabetic mice, which might be a compensative response to decreased plasma H~2~S levels. However, on day 8 after wounds, CSE activity in skin wounds of the diabetic mice was significantly attenuated and failed to produce enough H~2~S for wound healing, whereas CSE activity in the nondiabetic skin wounds was higher than at baseline, which might be a mechanism for the unchanged H~2~S levels. Because the expression of another H~2~S synthase, CBS, was not changed in skin tissue and in the EPCs of diabetic mice, the delayed wound healing in diabetic mice is more likely due to the deficiency of H~2~S synthesis in the vascular system, just as Brancaleone et al. ([@B19]) reported in NOD mice.

H~2~S had been found to improve the burn skin wound and gastric ulcers induced by acetate acid in wild-type mice or rats ([@B18]--[@B20]) and to improve endothelial wound healing in an in vitro model ([@B23]). Wallace et al. ([@B21]) revealed an enhancing effect of H~2~S in acetic acid--induced gastric ulcers in a Wistar rat model and in a skin burn wound model in CSE-knockout mice ([@B22]). This evidence suggests that H~2~S contributes to wound healing. However, no evidence of its efficacy on diabetic wounds has been reported so far.

In the current study, two H~2~S donors, NaHS and 4-HTB, were administrated in vivo; the first is the widely used rapid-releasing donor and the latter is the slow-releasing H~2~S donor. The usual dosage NaHS range is 10--100 μmol/kg, as reported in recent in vivo studies ([@B22],[@B23],[@B32]). On the basis of this evidence and considering that the physiological H~2~S levels in the plasma of mammals were 10--100 μmol/L ([@B42]), we chose 50 μmol/kg as the treatment dosage of NaHS in the current study. As for 4-HTB, only one experience, reported by Wallace et al. ([@B21]), could be referenced. They used HTB 10--30 μmol/kg twice daily by intragastric administration in male Wistar rats ([@B21]), so we administered the dose of 30 μmol/kg to diabetic mice and proved its efficacy on diabetic wound healing. The results of this study demonstrate that an intraperitoneal injection of the H~2~S donors NaHS and 4-HTB both improved the recovery rate of wound healing in type 2 diabetic mice and had similar effects on wound healing in diabetic mice. Because NaHS and 4-HTB are easily available H~2~S donors, they may be potential remedies to ameliorate foot ulcerations in diabetic patients.

Insufficient angiogenesis is one of most important reasons for delayed diabetic wound healing. The prominent functions of EPCs in angiogenesis have been widely demonstrated ([@B35],[@B43],[@B44]). In the current study, the tube formation and adhesive function of diabetic EPCs was impaired compared with normal mice with a matched genetic background, suggesting that their angiogenic effect was attenuated. The proangiogenic effect of H~2~S has been recently recognized. Cai et al. ([@B23]) reported a novel Akt-mediated proangiogenic role of H~2~S in C57BL/6 mice. Topical administration of H~2~S enhanced wound healing in CSE knockout mice, and the researchers concluded that endogenous H~2~S stimulates endothelial cell--related angiogenic properties through a ATP-sensitive K^+^ channel/mitogen-activated protein kinase pathway ([@B22]). H~2~S also enhances tube formation and migration in cultured vascular endothelial cells ([@B32]). The current study demonstrated that H~2~S donors facilitated diabetic wound healing by stimulating capillary formation at the site of injury. Furthermore, we demonstrated that the H~2~S donor accelerated EPC-mediated wound healing in diabetic mice. To date, whether H~2~S ameliorates diabetic wound healing by influencing EPC functions has not been elucidated.

In the current study, we first investigated the angiogenic effects of H~2~S donors on EPCs isolated from diabetic mice in vitro. Our results revealed that the tube formation and adhesion of EPCs increased significantly by chronic treatments with both the rapid-releasing and slow-releasing H~2~S donor in diabetic mice. Furthermore, the angiogenic function of diabetic EPCs also was restored by NaHS in vitro. These results support that H~2~S improves the angiogenic function of diabetic EPCs. On the contrary, after the normal mice and their EPCs were treated with the H~2~S synthetase (CSE) inhibitor DL-PAG in vivo and in vitro*,* or siCSE in vitro, the tube network formation and adhesive ability of normal EPCs declined markedly at the same time the wound closure rate was delayed. We have demonstrated that topical EPCs transplantation significantly improves wound healing in the diabetic mice ([@B35],[@B45]). In the current study, we found that NaHS significantly augmented the efficiency of EPC cell therapy in diabetic mice. Consistent with our previous studies, some EPCs integrated into vascular-like structures and the other EPCs integrated in the dermis at the early stage of wound beds (on day 8), indicating that H~2~S accelerates wound healing by EPC-mediated angiogenesis. Interestingly, we also found that more cells integrated into the epithelial layers at the later stage of wound beds (on day 16), which may be investigated in future studies. In vitro and in vivo evidence both suggests that H~2~S is vital for preserving normal EPC functions and wound repair in type 2 diabetic mice.

Angiogenic signals are mainly activated by endothelium-specific receptor tyrosine kinase, of which VEGF, fibroblast growth factor, and Ang-1 are ligands. Ang-1 promotes endothelial differentiation from embryonic stem cells and induces pluripotent stem cells ([@B46]). Ang-1 gene expression was downregulated in EPCs cultured in a high glucose environment, and recombinant Ang-1 increased the vessel-forming capacity of EPCs in vitro ([@B47]). The current study showed that in vivo treatment with H~2~S donors significantly increased the expressions of Ang-1 and VEGF in EPCs from diabetic mice. Most importantly, we also found attenuated expression of Ang-1 and VEGF in diabetic wounds in patients. Although the current study cannot exclude the effects of sex, medications, and comorbidities on the expressions of Ang-1, CSE, and VEGF, our results provided evidence that angiogenic factors and H~2~S were significantly attenuated in local diabetic wounds, which may contribute to refractory wounds in diabetic patients. Ang-1 was reported to potentiate VEGF-induced angiogenesis ([@B48]). Ang-1 signaling was known to regulate vascular quiescence and angiogenesis through its cognate receptor Tie-2 ([@B49]). However, we did not observe altered expression of the Ang-1 receptor Tie-2 between diabetic EPC or diabetic wounds. In parallel, the tube formation and adhesion ability of H~2~S-amended EPCs increased significantly, which was blocked by pretreatment by Ang-1 siRNA before H~2~S. These results suggest that the restoration of EPC angiogenic functions by H~2~S may occur, at least partly, through the mediation of Ang-1. H~2~S activates phosphatidylinositol-3-kinase and mitogen-activated protein kinases to regulate angiogenic factors in endothelial cells ([@B22],[@B50],[@B51]). However, the mechanisms by which H~2~S regulates Ang-1 in EPCs are still unknown. Further research should be done to clarify how and to what degree H~2~S improves diabetic wound healing and EPC function via Ang-1.

In summary, the current study demonstrates for the first time that H~2~S is vital in maintaining normal EPC angiogenic function and that an H~2~S donor can accelerate wound healing in type 2 diabetic mice. These effects of H~2~S are related to restoring the angiogenic functions of EPCs by upregulating Ang-1 expression. The findings that an H~2~S donor can amend EPC function and improve skin wound recovery may lead to novel therapeutic strategies for diabetic vascular complications and diabetic skin ulcerations.
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